TrialHypertension (Dallas, Tex. : 1979)2019

Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.

Tariq E Farrah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.